SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 16, 2003
AVANIR PHARMACEUTICALS
| California | 001-15803 | 33-0314804 | ||
| (State of Incorporation or Organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
| 11388 Sorrento Valley Road, Suite 200, San Diego, California | 92121 | |||||
| (Address of Principal Executive Offices) |
|
(Zip Code) |
||||
Registrant’s telephone number, including area code: (858) 622-5200
NOT APPLICABLE
| Item 7. Financial Statements and Exhibits. | ||||||||
| Item 12. Results of Operations and Financial Condition. | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 7. Financial Statements and Exhibits.
| Exhibit |
| 99.1 | Press release, dated December 16, 2003 |
Item 12. Results of Operations and Financial Condition.
On December 16, 2003, AVANIR Pharmaceuticals issued a press release announcing its results of operations for the quarter and year ended September 30, 2003. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: December 16, 2003
| AVANIR PHARMACEUTICALS | ||||||
| By: | /s/ Gregory P. Hanson | |||||
| Gregory P. Hanson | ||||||
| Chief Financial Officer | ||||||
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press release, dated December 16, 2003 |